Package Leaflet: Information for the User
Ebastina Quasset 10 mg Oral Disintegrating Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet
Ebastina Quasset belongs to a group of medications called antihistamines (anti-allergics).
Ebastina Quasset is indicated for the treatment of symptoms of allergic processes such as seasonal or perennial allergic rhinitis, with or without allergic conjunctivitis (such as nasal discharge, nasal itching, eye itching, tearing, sneezing), chronic urticaria, and allergic dermatitis.
Do not takeEbastina Quasset
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Ebastina Quasset.
Do not use this medication if you have an acute allergic emergency, as ebastine (the active ingredient of this medication) takes 1 to 3 hours to take effect.
Children
Ebastina Quasset should not be administered to children under 12 years of age.
Taking Ebastina Quasset with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
The medications listed below may interfere with ebastine; in these cases, it may be necessary to change the dose or discontinue treatment with one of them:
This is because Ebastina Quasset may interfere with the way some medications work, and some of them may have an effect on Ebastina Quasset.
Interference with Diagnostic Tests
Ebastina Quasset may interfere with the results of skin allergy tests, so it is recommended not to perform them until 5-7 days after discontinuing treatment.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
There is no experience in pregnant women, so it is recommended to consult a doctor before taking Ebastel Flas. The doctor will decide whether or not to initiate treatment.
Breastfeeding
It is unknown whether the medication passes into breast milk, so it should not be used during breastfeeding.
In humans, no effects on psychomotor function or the ability to drive or operate machinery have been observed at the recommended therapeutic doses. However, since side effects include drowsiness and dizziness, observe your response to treatment before driving or operating machinery.
Ebastina Quasset oral disintegrating tablets contain aspartame (E-951)
This medication may be harmful to people with phenylketonuria because it contains aspartame, which is a source of phenylalanine.
Ebastina Quasset oral disintegrating tablets containlactose
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1mmol) per tablet; this is essentially "sodium-free".
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If you have any doubts, consult your doctor or pharmacist again.
Remember to take your medication.
Your doctor will indicate the duration of treatment with Ebastina Quasset.
Dosage
Use in Adults and Children Over 12 Years
The recommended dose is 1 oral disintegrating tablet (10 mg of ebastine) once a day.
Use in Patients with Severe Liver Disease
Do not exceed the dose of 10 mg of ebastine per day (1 tablet).
Method of Administration
This medication is for oral administration.
If You Take More Ebastina Quasset Than You Should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20 (indicating the medication and the amount ingested) or go to the nearest hospital. Bring the remaining tablets, the box, and the complete package so that the healthcare personnel can more easily identify the medication you have taken.
Treatment of poisoning with this medication consists of gastric lavage and administration of the appropriate medication.
If You Forget to Take Ebastina Quasset
Do not take a double dose to make up for the missed doses. Take the missed dose as soon as you remember and then continue taking this medication with your regular schedule. However, if it is almost time for your next dose, do not take the missed dose and wait for the next scheduled dose.
If you have any doubts about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
The following side effects have been observed in clinical trials and post-marketing experience:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 1,000 people):
Frequency not known (cannot be estimated from available data)
-Weight gain
-Increased appetite
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date shown on the box after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the SIGRE collection point at the pharmacy. If you have any doubts, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Ebastina Quasset:
Appearance of the Product and Package Contents
Ebastina Quasset 10 mg is presented in the form of white, round oral disintegrating tablets with a diameter of 6.5 mm, packaged in blisters.
Package size: 20 oral disintegrating tablets.
Marketing Authorization Holder and Manufacturer:
Marketing Authorization Holder:
Industria Química y Farmacéutica VIR, S.A.
C/ Laguna 66-70, Polígono Industrial URTINSA II
28923 Alcorcón (Madrid)
Spain
Manufacturer:
SEID, S.A.
Carretera de Sabadell a Granollers Km 15
08185 Lliçà de Vall – Barcelona
Spain
Date of the Last Revision of this Package Leaflet:September 2020
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/